<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03145766</url>
  </required_header>
  <id_info>
    <org_study_id>VRV11</org_study_id>
    <secondary_id>U1111-1174-4976</secondary_id>
    <nct_id>NCT03145766</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of a Purified Vero Rabies Vaccine</brief_title>
  <official_title>Immunogenicity and Safety of a Purified Vero Rabies Vaccine - Serum Free When Administered According to a Simulated Rabies Post-exposure Regimen in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter, observer-blind, controlled, randomized, Phase II study was designed to&#xD;
      evaluate different formulations of the Purified Vero Rabies Cell vaccine VRVg.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study assessed different formulations of the modified formulation of VRVg (VRVg 2-&#xD;
      formulations 1 [low], 2 [medium] and 3 [high]) tested in parallel to the initial VRVg&#xD;
      formulation (VRVg-1) and Imovax Rabies. Immune responses were assessed at Day 14, Day 28, Day&#xD;
      42, and at Month 7. Safety events were also reported.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 17, 2017</start_date>
  <completion_date type="Actual">January 8, 2018</completion_date>
  <primary_completion_date type="Actual">January 8, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rabies Virus Neutralizing Antibody (RVNA) Geometric Mean Titers (GMTs) Against Rabies Virus at Day 0</measure>
    <time_frame>Day 0</time_frame>
    <description>RVNA GMT against rabies virus was assessed using the rapid fluorescent focus inhibition test (RFFIT) assay method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rabies Virus Neutralizing Antibody Geometric Mean Titers Against Rabies Virus at Day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>RVNA GMT against rabies virus was assessed using the RFFIT assay method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rabies Virus Neutralizing Antibody Geometric Mean Titers Against Rabies Virus at Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>RVNA GMT against rabies virus was assessed using the RFFIT assay method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rabies Virus Neutralizing Antibody Geometric Mean Titers Against Rabies Virus at Day 42</measure>
    <time_frame>Day 42</time_frame>
    <description>RVNA GMT against rabies virus was assessed using the RFFIT assay method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rabies Virus Neutralizing Antibody Geometric Mean Titers Against Rabies Virus at Month 7</measure>
    <time_frame>Month 7</time_frame>
    <description>RVNA GMT against rabies virus was assessed using the RFFIT assay method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Rabies Virus Neutralizing Antibody Titer Greater Than or Equal to (&gt;=) 0.2 IU/mL and &gt;=0.5 IU/mL at Day 0</measure>
    <time_frame>Day 0</time_frame>
    <description>RVNA titer against rabies virus was assessed using the RFFIT assay method. Participants with RVNA titer &gt;=0.2 IU/mL were considered as seropositive.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Rabies Virus Neutralizing Antibody Titers &gt;=0.2 IU/mL and &gt;=0.5 IU/mL at Day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>RVNA titer against rabies virus was assessed using the RFFIT assay method. Participants with RVNA titer &gt;=0.2 IU/mL were considered as seropositive.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With RVNA Titers &gt;=0.2 IU/mL and &gt;=0.5 IU/mL at Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>RVNA titer against rabies virus was assessed using the RFFIT assay method. Participants with RVNA titer &gt;=0.2 IU/mL were considered as seropositive.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With RVNA Titers &gt;=0.2 IU/mL and &gt;=0.5 IU/mL at Day 42</measure>
    <time_frame>Day 42</time_frame>
    <description>RVNA titer against rabies virus was assessed using the RFFIT assay method. Participants with RVNA titer &gt;=0.2 IU/mL were considered as seropositive.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With RVNA Titers &gt;=0.2 IU/mL and &gt;=0.5 IU/mL at Month 7</measure>
    <time_frame>Month 7</time_frame>
    <description>RVNA titer against rabies virus was assessed using the RFFIT assay method. Participants with RVNA titer &gt;= 0.2 IU/mL were considered as seropositive.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer Ratio (GMTR) of Rabies Virus Neutralizing Antibody 7 Days Following Vaccination 3 (Day 14/Day 0)</measure>
    <time_frame>Day 0 (pre-dose) and Day 14 (7 days post-dose 3)</time_frame>
    <description>RVNA titer against rabies virus was assessed using the RFFIT assay method. GMTRs were calculated as the ratio of GMTs 7 days post 3rd vaccination (i.e., on Day 14) and pre-vaccination on Day 0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer Ratio of Rabies Virus Neutralizing Antibody 14 Days Following Vaccination 4 (Day 28/Day 0)</measure>
    <time_frame>Day 0 (pre-dose) and Day 28 (14 days post-dose 4)</time_frame>
    <description>RVNA titer against rabies virus was assessed using the RFFIT assay method. GMTRs were calculated as the ratio of GMTs 14 days post 4th vaccination (i.e., on Day 28) and pre-vaccination on Day 0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer Ratio of Rabies Virus Neutralizing Antibody 14 Days Following Vaccination 5 (Day 42/Day 0)</measure>
    <time_frame>Day 0 (Pre-dose) and Day 42 (14 days Post-dose 5)</time_frame>
    <description>RVNA titer against rabies virus was assessed using the RFFIT assay method. GMTRs were calculated as the ratio of GMTs 14 days post 5th vaccination (i.e., on Day 42) and pre-vaccination on Day 0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer Ratio of Rabies Virus Neutralizing Antibody 6 Months Following Last Vaccination (Month 7/Day 0)</measure>
    <time_frame>Day 0 (Pre-dose) and Month 7 (6 Months Post Last Vaccination)</time_frame>
    <description>RVNA titer against rabies virus was assessed using the RFFIT assay method. GMTRs were calculated as the ratio of GMTs 6 month post last vaccination on Month 7 and pre-vaccination on Day 0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Complete Virus Neutralization at Starting Dilution (1/5) of Rapid Fluorescent Focus Inhibition Test Assay at Day 0</measure>
    <time_frame>Day 0</time_frame>
    <description>Complete virus neutralization was defined as absence of fluorescent cells at the participant/time point level at the starting dilution (1/5) of the RFFIT assay. Percentage of participants with complete virus neutralization were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Complete Virus Neutralization at Starting Dilution (1/5) of Rapid Fluorescent Focus Inhibition Test Assay at Day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>Complete virus neutralization was defined as absence of fluorescent cells at the participant/time point level at the starting dilution (1/5) of the RFFIT assay. Percentage of participants with complete virus neutralization were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Complete Virus Neutralization at Starting Dilution (1/5) of Rapid Fluorescent Focus Inhibition Test Assay at Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>Complete virus neutralization was defined as absence of fluorescent cells at the participant/time point level at the starting dilution (1/5) of the RFFIT assay. Percentage of participants with complete virus neutralization were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Complete Virus Neutralization at Starting Dilution (1/5) of Rapid Fluorescent Focus Inhibition Test Assay at Day 42</measure>
    <time_frame>Day 42</time_frame>
    <description>Complete virus neutralization was defined as absence of fluorescent cells at the participant/time point level at the starting dilution (1/5) of the RFFIT assay. Percentage of participants with complete virus neutralization were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Complete Virus Neutralization at Starting Dilution (1/5) of Rapid Fluorescent Focus Inhibition Test Assay at Month 7</measure>
    <time_frame>Month 7</time_frame>
    <description>Complete virus neutralization was defined as absence of fluorescent cells at the participant/time point level at the starting dilution (1/5) of the RFFIT assay. Percentage of participants with complete virus neutralization were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Immediate Unsolicited Adverse Events</measure>
    <time_frame>Within 30 Minutes After any Vaccination</time_frame>
    <description>An adverse event was defined as any untoward medical occurrence in a participant who received study drug and does not necessary have to have a causal relationship with treatment. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report form (CRF) in terms of diagnosis and/or onset post-vaccination. All participants were observed for 30 minutes after any vaccination, and any unsolicited AEs occurred during that time were recorded as immediate unsolicited AEs in the CRF. Immediate AEs considered as related to vaccination were recorded as immediate unsolicited adverse reactions (ARs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With at Least One Solicited Injection Site Reactions</measure>
    <time_frame>Within 7 Days After any and each vaccination (Vaccination 1, 2, 3, 4 and 5)</time_frame>
    <description>A solicited reaction (SR) was an AR observed and reported under conditions (symptoms and onset) prelisted (i.e., solicited) in the CRF and considered as related to vaccination. An AR was all noxious and unintended responses to a medicinal product related to any dose. Solicited injection site reactions included pain, erythema and swelling at and around the injection site.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With at Least One Solicited Systemic Reactions</measure>
    <time_frame>Within 7 Days After any and each vaccination (Vaccination 1, 2, 3, 4 and 5)</time_frame>
    <description>A solicited reaction was an AR observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the CRF and considered as related to vaccination. An AR was all noxious and unintended responses to a medicinal product related to any dose. Solicited systemic reactions included fever, headache, malaise and myalgia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With at Least One Unsolicited Adverse Events</measure>
    <time_frame>Within 28 Days After any vaccination</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a participant who received study drug and does not necessary have to have a causal relationship with treatment. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the CRF in terms of diagnosis and/or onset post-vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs)</measure>
    <time_frame>From Day 0 up to Month 7</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a participant who received study drug and does not necessary have to have a causal relationship with treatment. An SAE was any untoward medical occurrence that at any dose resulted in death; life-threatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect or a medically important event.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">320</enrollment>
  <condition>Rabies Virus</condition>
  <arm_group>
    <arm_group_label>Group 1: VRVg-2 Formulation 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VRVg-2 formulation 1, intramuscular (IM) injection on Days 0, 3, 7, 14 and 28. Concomitant administration of human rabies immunoglobulins (HRIG) on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: VRVg-2 Formulation 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VRVg-2 formulation 2, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: VRVg-2 Formulation 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VRVg-2 formulation 3, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: VRVg-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: Imovax Rabies</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VRVg 2</intervention_name>
    <description>Modified formulation 1 (Low) of Purified Vero Rabies Vaccine Serum Free</description>
    <arm_group_label>Group 1: VRVg-2 Formulation 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VRVg 1</intervention_name>
    <description>Initial formulation of Purified Vero Rabies Vaccine Serum Free</description>
    <arm_group_label>Group 4: VRVg-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Imovax Rabies</intervention_name>
    <description>Purified inactivated rabies vaccine prepared on human diploid cell cultures</description>
    <arm_group_label>Group 5: Imovax Rabies</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VRVg 2</intervention_name>
    <description>Modified formulation 2 (Medium) of Purified Vero Rabies Vaccine Serum Free</description>
    <arm_group_label>Group 2: VRVg-2 Formulation 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VRVg 2</intervention_name>
    <description>Modified formulation 3 (High) of Purified Vero Rabies Vaccine Serum Free</description>
    <arm_group_label>Group 3: VRVg-2 Formulation 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Human Rabies Immunoglobulins (HRIG)</intervention_name>
    <description>Commercialized formulation of HRIG</description>
    <arm_group_label>Group 1: VRVg-2 Formulation 1</arm_group_label>
    <arm_group_label>Group 2: VRVg-2 Formulation 2</arm_group_label>
    <arm_group_label>Group 3: VRVg-2 Formulation 3</arm_group_label>
    <arm_group_label>Group 4: VRVg-1</arm_group_label>
    <arm_group_label>Group 5: Imovax Rabies</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        An individual must fulfill all of the following criteria in order to be eligible for trial&#xD;
        enrollment:&#xD;
&#xD;
          1. Aged 18 to less than 65 years on the day of inclusion.&#xD;
&#xD;
          2. Informed consent form had been signed and dated.&#xD;
&#xD;
          3. Able to attend all scheduled visits and to complied with all trial procedures.&#xD;
&#xD;
          4. Body Mass Index (BMI): 18.5 kilograms per meter square (Kg/m^2) less than or equal to&#xD;
             (&lt;=) BMI &lt;= 30 Kg/m^2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        An individual fulfilling any of the following criteria was to be excluded from trial&#xD;
        enrollment:&#xD;
&#xD;
          1. Participant was pregnant, or lactating, or of childbearing potential and not using an&#xD;
             effective method of contraception or abstinence from at least 4 weeks prior to the&#xD;
             first vaccination until at least 4 weeks after the last vaccination. To be considered&#xD;
             of non-childbearing potential, a female must be post-menopausal for at least 1 year,&#xD;
             or surgically sterile.&#xD;
&#xD;
          2. Participation at the time of study enrollment or, planned participation during the&#xD;
             present trial period in another clinical trial investigating a vaccine, drug, medical&#xD;
             device, or medical procedure.&#xD;
&#xD;
          3. Receipt of any vaccine in the 4 weeks (28 days) preceding the first trial vaccination&#xD;
             or planned receipt of any vaccine prior to Visit 6.&#xD;
&#xD;
          4. Previous vaccination against rabies (in pre- or post-exposure regimen) with either the&#xD;
             trial vaccine or another vaccine.&#xD;
&#xD;
          5. Receipt of immune globulins, blood or blood-derived products in the past 3 months.&#xD;
&#xD;
          6. Known or suspected congenital or acquired immunodeficiency; or receipt of&#xD;
             immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy,&#xD;
             within the preceding 6 months; or long-term systemic corticosteroid therapy&#xD;
             (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).&#xD;
&#xD;
          7. At high risk for rabies infection during the trial (e.g., veterinarians and staff,&#xD;
             animal handlers, rabies researchers, or any others whose activities may bring them&#xD;
             into frequent contact with rabies virus or animals who had the rabies virus).&#xD;
&#xD;
          8. Known systemic hypersensitivity to any of the vaccine or human rabies immunoglobulins&#xD;
             (HRIG) components, or history of a life-threatening reaction to the vaccines used in&#xD;
             the trial or to a vaccine containing any of the same substances.&#xD;
&#xD;
          9. Self-reported thrombocytopenia, contraindicating IM vaccination.&#xD;
&#xD;
         10. Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion,&#xD;
             contraindicating IM vaccination.&#xD;
&#xD;
         11. Deprived of freedom by an administrative or court order, or in an emergency setting,&#xD;
             or hospitalized involuntarily.&#xD;
&#xD;
         12. Current alcohol abuse or drug addiction.&#xD;
&#xD;
         13. Chronic illness that, in the opinion of the investigator, was at a stage where it&#xD;
             might interfere with trial conduct or completion (e.g., cardiac disorders, renal&#xD;
             disorders, auto immune disorders, diabetes, psychiatric disorders or chronic&#xD;
             infection).&#xD;
&#xD;
         14. Moderate or severe acute illness/infection (according to investigator judgment) on the&#xD;
             day of vaccination or febrile illness (temperature greater than or equal to [&gt;=] 100.4&#xD;
             Fahrenheit &gt;=38.0 Celsius). A prospective participant should not be included in the&#xD;
             study until the condition had resolved or the febrile event had subsided.&#xD;
&#xD;
         15. Identified as an Investigator or employee of the Investigator or study center with&#xD;
             direct involvement in the proposed study, or identified as an immediate family member&#xD;
             (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with&#xD;
             direct involvement in the proposed study.&#xD;
&#xD;
         16. History of Guillain-Barr√© syndrome.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Redding</city>
        <state>California</state>
        <zip>96001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 3, 2017</study_first_submitted>
  <study_first_submitted_qc>May 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2017</study_first_posted>
  <results_first_submitted>January 7, 2021</results_first_submitted>
  <results_first_submitted_qc>January 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 28, 2021</results_first_posted>
  <disposition_first_submitted>January 24, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>January 24, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 28, 2019</disposition_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rabies virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT03145766/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 17, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT03145766/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 5 centers in the United States from 17 April 2017 to 08 January 2018.</recruitment_details>
      <pre_assignment_details>A total of 320 participants were enrolled and vaccinated in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: VRVg-2 Formulation 1</title>
          <description>VRVg-2 formulation 1 (Low), intramuscular (IM) injection on Days 0, 3, 7, 14 and 28. Concomitant administration of human rabies immunoglobulins (HRIG) on Day 0.</description>
        </group>
        <group group_id="P2">
          <title>Group 2:VRVg-2 Formulation 2</title>
          <description>VRVg-2 formulation 2 (Medium), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
        </group>
        <group group_id="P3">
          <title>Group 3: VRVg-2 Formulation 3</title>
          <description>VRVg-2 formulation 3 (High), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
        </group>
        <group group_id="P4">
          <title>Group 4: VRVg-1</title>
          <description>VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
        </group>
        <group group_id="P5">
          <title>Group 5: Imovax Rabies</title>
          <description>Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Active Vaccination Phase (Day 0-Day 56)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="80"/>
                <participants group_id="P3" count="80"/>
                <participants group_id="P4" count="40"/>
                <participants group_id="P5" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 1</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="80"/>
                <participants group_id="P3" count="80"/>
                <participants group_id="P4" count="39">1 participant of this arm received Imovax Rabies, and counted in Group 5 for safety analysis.</participants>
                <participants group_id="P5" count="41">1 participant of Group 4 received Imovax Rabies, and counted in Group 5 for safety analysis.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 2</title>
              <participants_list>
                <participants group_id="P1" count="77">1 participant received Group 2 vaccine: counted in Group 2 for post-vaccination 2 safety analysis.</participants>
                <participants group_id="P2" count="81">1 participant of Group 1 received Group 2 vaccine: counted in Group 2 for post-vaccination 2 safety.</participants>
                <participants group_id="P3" count="80"/>
                <participants group_id="P4" count="39"/>
                <participants group_id="P5" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 3</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="79"/>
                <participants group_id="P3" count="80"/>
                <participants group_id="P4" count="39"/>
                <participants group_id="P5" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 4</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="79"/>
                <participants group_id="P3" count="80"/>
                <participants group_id="P4" count="38"/>
                <participants group_id="P5" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 5</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="78"/>
                <participants group_id="P3" count="79"/>
                <participants group_id="P4" count="34"/>
                <participants group_id="P5" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="77"/>
                <participants group_id="P3" count="78"/>
                <participants group_id="P4" count="33"/>
                <participants group_id="P5" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other Adverse Event (AE)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with the Protocol</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Voluntary Withdrawal Not Due AE</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-up Phase (Day 56 Till Month 7)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="77"/>
                <participants group_id="P3" count="78"/>
                <participants group_id="P4" count="33"/>
                <participants group_id="P5" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="75"/>
                <participants group_id="P3" count="73"/>
                <participants group_id="P4" count="30"/>
                <participants group_id="P5" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Non-compliance with the Protocol</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Voluntary Withdrawal not due to AE</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis was performed on all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1: VRVg-2 Formulation 1</title>
          <description>VRVg-2 formulation 1 (Low), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
        </group>
        <group group_id="B2">
          <title>Group 2:VRVg-2 Formulation 2</title>
          <description>VRVg-2 formulation 2 (Medium), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
        </group>
        <group group_id="B3">
          <title>Group 3: VRVg-2 Formulation 3</title>
          <description>VRVg-2 formulation 3 (High), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
        </group>
        <group group_id="B4">
          <title>Group 4: VRVg-1</title>
          <description>VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
        </group>
        <group group_id="B5">
          <title>Group 5: Imovax Rabies</title>
          <description>Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
            <count group_id="B2" value="80"/>
            <count group_id="B3" value="80"/>
            <count group_id="B4" value="40"/>
            <count group_id="B5" value="40"/>
            <count group_id="B6" value="320"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.9" spread="13.4"/>
                    <measurement group_id="B2" value="42.6" spread="13.0"/>
                    <measurement group_id="B3" value="41.1" spread="14.4"/>
                    <measurement group_id="B4" value="41.1" spread="13.5"/>
                    <measurement group_id="B5" value="38.9" spread="13.1"/>
                    <measurement group_id="B6" value="41.4" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="158"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="217"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rabies Virus Neutralizing Antibody (RVNA) Geometric Mean Titers (GMTs) Against Rabies Virus at Day 0</title>
        <description>RVNA GMT against rabies virus was assessed using the rapid fluorescent focus inhibition test (RFFIT) assay method.</description>
        <time_frame>Day 0</time_frame>
        <population>Per-Protocol Analysis Set (PPAS): participants who received at least one dose of the study vaccine without protocol deviations before Day 14 (i.e., 7 days after the 3rd vaccine injection).</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: VRVg-2 Formulation 1</title>
            <description>VRVg-2 formulation 1 (Low), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Group 2:VRVg-2 Formulation 2</title>
            <description>VRVg-2 formulation 2 (Medium), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: VRVg-2 Formulation 3</title>
            <description>VRVg-2 formulation 3 (High), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: VRVg-1</title>
            <description>VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Imovax Rabies</title>
            <description>Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Rabies Virus Neutralizing Antibody (RVNA) Geometric Mean Titers (GMTs) Against Rabies Virus at Day 0</title>
          <description>RVNA GMT against rabies virus was assessed using the rapid fluorescent focus inhibition test (RFFIT) assay method.</description>
          <population>Per-Protocol Analysis Set (PPAS): participants who received at least one dose of the study vaccine without protocol deviations before Day 14 (i.e., 7 days after the 3rd vaccine injection).</population>
          <units>international units per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.101" lower_limit="0.099" upper_limit="0.102"/>
                    <measurement group_id="O2" value="0.100" lower_limit="NA" upper_limit="NA">Upper and lower limit of 95% confidence interval (CI) was not estimable because all the participants had same value and no variability was observed.</measurement>
                    <measurement group_id="O3" value="0.102" lower_limit="0.099" upper_limit="0.104"/>
                    <measurement group_id="O4" value="0.101" lower_limit="0.099" upper_limit="0.103"/>
                    <measurement group_id="O5" value="0.100" lower_limit="NA" upper_limit="NA">Upper and lower limit of 95% CI was not estimable because all the participants had same value and no variability was observed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rabies Virus Neutralizing Antibody Geometric Mean Titers Against Rabies Virus at Day 14</title>
        <description>RVNA GMT against rabies virus was assessed using the RFFIT assay method.</description>
        <time_frame>Day 14</time_frame>
        <population>Analysis was performed on PPAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: VRVg-2 Formulation 1</title>
            <description>VRVg-2 formulation 1 (Low), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Group 2:VRVg-2 Formulation 2</title>
            <description>VRVg-2 formulation 2 (Medium), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: VRVg-2 Formulation 3</title>
            <description>VRVg-2 formulation 3 (High), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: VRVg-1</title>
            <description>VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Imovax Rabies</title>
            <description>Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Rabies Virus Neutralizing Antibody Geometric Mean Titers Against Rabies Virus at Day 14</title>
          <description>RVNA GMT against rabies virus was assessed using the RFFIT assay method.</description>
          <population>Analysis was performed on PPAS.</population>
          <units>international units per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" lower_limit="0.944" upper_limit="1.73"/>
                    <measurement group_id="O2" value="1.79" lower_limit="1.33" upper_limit="2.41"/>
                    <measurement group_id="O3" value="2.52" lower_limit="1.93" upper_limit="3.28"/>
                    <measurement group_id="O4" value="1.38" lower_limit="0.936" upper_limit="2.05"/>
                    <measurement group_id="O5" value="1.56" lower_limit="1.06" upper_limit="2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rabies Virus Neutralizing Antibody Geometric Mean Titers Against Rabies Virus at Day 28</title>
        <description>RVNA GMT against rabies virus was assessed using the RFFIT assay method.</description>
        <time_frame>Day 28</time_frame>
        <population>Analysis was performed on PPAS. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: VRVg-2 Formulation 1</title>
            <description>VRVg-2 formulation 1 (Low), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Group 2:VRVg-2 Formulation 2</title>
            <description>VRVg-2 formulation 2 (Medium), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: VRVg-2 Formulation 3</title>
            <description>VRVg-2 formulation 3 (High), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: VRVg-1</title>
            <description>VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Imovax Rabies</title>
            <description>Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Rabies Virus Neutralizing Antibody Geometric Mean Titers Against Rabies Virus at Day 28</title>
          <description>RVNA GMT against rabies virus was assessed using the RFFIT assay method.</description>
          <population>Analysis was performed on PPAS. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.</population>
          <units>international units per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.22" lower_limit="2.48" upper_limit="4.17"/>
                    <measurement group_id="O2" value="4.64" lower_limit="3.53" upper_limit="6.10"/>
                    <measurement group_id="O3" value="6.81" lower_limit="5.52" upper_limit="8.39"/>
                    <measurement group_id="O4" value="3.04" lower_limit="1.86" upper_limit="4.95"/>
                    <measurement group_id="O5" value="4.86" lower_limit="3.56" upper_limit="6.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rabies Virus Neutralizing Antibody Geometric Mean Titers Against Rabies Virus at Day 42</title>
        <description>RVNA GMT against rabies virus was assessed using the RFFIT assay method.</description>
        <time_frame>Day 42</time_frame>
        <population>Analysis was performed on PPAS. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: VRVg-2 Formulation 1</title>
            <description>VRVg-2 formulation 1 (Low), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Group 2:VRVg-2 Formulation 2</title>
            <description>VRVg-2 formulation 2 (Medium), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: VRVg-2 Formulation 3</title>
            <description>VRVg-2 formulation 3 (High), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: VRVg-1</title>
            <description>VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Imovax Rabies</title>
            <description>Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Rabies Virus Neutralizing Antibody Geometric Mean Titers Against Rabies Virus at Day 42</title>
          <description>RVNA GMT against rabies virus was assessed using the RFFIT assay method.</description>
          <population>Analysis was performed on PPAS. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.</population>
          <units>international units per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.14" lower_limit="6.60" upper_limit="10.0"/>
                    <measurement group_id="O2" value="9.68" lower_limit="7.50" upper_limit="12.5"/>
                    <measurement group_id="O3" value="15.6" lower_limit="12.7" upper_limit="19.1"/>
                    <measurement group_id="O4" value="6.98" lower_limit="4.69" upper_limit="10.4"/>
                    <measurement group_id="O5" value="8.99" lower_limit="6.48" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rabies Virus Neutralizing Antibody Geometric Mean Titers Against Rabies Virus at Month 7</title>
        <description>RVNA GMT against rabies virus was assessed using the RFFIT assay method.</description>
        <time_frame>Month 7</time_frame>
        <population>Analysis was performed on PPAS. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: VRVg-2 Formulation 1</title>
            <description>VRVg-2 formulation 1 (Low), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Group 2:VRVg-2 Formulation 2</title>
            <description>VRVg-2 formulation 2 (Medium), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: VRVg-2 Formulation 3</title>
            <description>VRVg-2 formulation 3 (High), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: VRVg-1</title>
            <description>VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Imovax Rabies</title>
            <description>Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Rabies Virus Neutralizing Antibody Geometric Mean Titers Against Rabies Virus at Month 7</title>
          <description>RVNA GMT against rabies virus was assessed using the RFFIT assay method.</description>
          <population>Analysis was performed on PPAS. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.</population>
          <units>international units per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.894" lower_limit="0.667" upper_limit="1.20"/>
                    <measurement group_id="O2" value="0.971" lower_limit="0.768" upper_limit="1.23"/>
                    <measurement group_id="O3" value="1.58" lower_limit="1.28" upper_limit="1.94"/>
                    <measurement group_id="O4" value="0.939" lower_limit="0.634" upper_limit="1.39"/>
                    <measurement group_id="O5" value="1.01" lower_limit="0.649" upper_limit="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Rabies Virus Neutralizing Antibody Titer Greater Than or Equal to (&gt;=) 0.2 IU/mL and &gt;=0.5 IU/mL at Day 0</title>
        <description>RVNA titer against rabies virus was assessed using the RFFIT assay method. Participants with RVNA titer &gt;=0.2 IU/mL were considered as seropositive.</description>
        <time_frame>Day 0</time_frame>
        <population>Analysis was performed on PPAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: VRVg-2 Formulation 1</title>
            <description>VRVg-2 formulation 1 (Low), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Group 2:VRVg-2 Formulation 2</title>
            <description>VRVg-2 formulation 2 (Medium), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: VRVg-2 Formulation 3</title>
            <description>VRVg-2 formulation 3 (High), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: VRVg-1</title>
            <description>VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Imovax Rabies</title>
            <description>Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Rabies Virus Neutralizing Antibody Titer Greater Than or Equal to (&gt;=) 0.2 IU/mL and &gt;=0.5 IU/mL at Day 0</title>
          <description>RVNA titer against rabies virus was assessed using the RFFIT assay method. Participants with RVNA titer &gt;=0.2 IU/mL were considered as seropositive.</description>
          <population>Analysis was performed on PPAS.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RVNA titer &gt;= 0.2 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="4.8"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="5.1"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="10.0"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RVNA titer &gt;= 0.5 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="4.8"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="5.1"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="10.0"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Rabies Virus Neutralizing Antibody Titers &gt;=0.2 IU/mL and &gt;=0.5 IU/mL at Day 14</title>
        <description>RVNA titer against rabies virus was assessed using the RFFIT assay method. Participants with RVNA titer &gt;=0.2 IU/mL were considered as seropositive.</description>
        <time_frame>Day 14</time_frame>
        <population>Analysis was performed on PPAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: VRVg-2 Formulation 1</title>
            <description>VRVg-2 formulation 1 (Low), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Group 2:VRVg-2 Formulation 2</title>
            <description>VRVg-2 formulation 2 (Medium), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: VRVg-2 Formulation 3</title>
            <description>VRVg-2 formulation 3 (High), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: VRVg-1</title>
            <description>VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Imovax Rabies</title>
            <description>Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Rabies Virus Neutralizing Antibody Titers &gt;=0.2 IU/mL and &gt;=0.5 IU/mL at Day 14</title>
          <description>RVNA titer against rabies virus was assessed using the RFFIT assay method. Participants with RVNA titer &gt;=0.2 IU/mL were considered as seropositive.</description>
          <population>Analysis was performed on PPAS.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RVNA titer &gt;= 0.2 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.1" lower_limit="84.5" upper_limit="97.7"/>
                    <measurement group_id="O2" value="96.0" lower_limit="88.8" upper_limit="99.2"/>
                    <measurement group_id="O3" value="97.2" lower_limit="90.2" upper_limit="99.7"/>
                    <measurement group_id="O4" value="97.1" lower_limit="85.1" upper_limit="99.9"/>
                    <measurement group_id="O5" value="97.1" lower_limit="84.7" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RVNA titer &gt;= 0.5 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="63.4" upper_limit="84.5"/>
                    <measurement group_id="O2" value="81.3" lower_limit="70.7" upper_limit="89.4"/>
                    <measurement group_id="O3" value="90.1" lower_limit="80.7" upper_limit="95.9"/>
                    <measurement group_id="O4" value="80.0" lower_limit="63.1" upper_limit="91.6"/>
                    <measurement group_id="O5" value="88.2" lower_limit="72.5" upper_limit="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With RVNA Titers &gt;=0.2 IU/mL and &gt;=0.5 IU/mL at Day 28</title>
        <description>RVNA titer against rabies virus was assessed using the RFFIT assay method. Participants with RVNA titer &gt;=0.2 IU/mL were considered as seropositive.</description>
        <time_frame>Day 28</time_frame>
        <population>Analysis was performed on PPAS. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: VRVg-2 Formulation 1</title>
            <description>VRVg-2 formulation 1 (Low), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Group 2:VRVg-2 Formulation 2</title>
            <description>VRVg-2 formulation 2 (Medium), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: VRVg-2 Formulation 3</title>
            <description>VRVg-2 formulation 3 (High), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: VRVg-1</title>
            <description>VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Imovax Rabies</title>
            <description>Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With RVNA Titers &gt;=0.2 IU/mL and &gt;=0.5 IU/mL at Day 28</title>
          <description>RVNA titer against rabies virus was assessed using the RFFIT assay method. Participants with RVNA titer &gt;=0.2 IU/mL were considered as seropositive.</description>
          <population>Analysis was performed on PPAS. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RVNA titers &gt;= 0.2 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5" lower_limit="91.8" upper_limit="100"/>
                    <measurement group_id="O2" value="98.6" lower_limit="92.6" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="94.7" upper_limit="100"/>
                    <measurement group_id="O4" value="96.6" lower_limit="82.2" upper_limit="99.9"/>
                    <measurement group_id="O5" value="100" lower_limit="89.4" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RVNA titers &gt;= 0.5 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.9" lower_limit="85.2" upper_limit="98.3"/>
                    <measurement group_id="O2" value="95.9" lower_limit="88.5" upper_limit="99.1"/>
                    <measurement group_id="O3" value="100" lower_limit="94.7" upper_limit="100"/>
                    <measurement group_id="O4" value="86.2" lower_limit="68.3" upper_limit="96.1"/>
                    <measurement group_id="O5" value="100" lower_limit="89.4" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With RVNA Titers &gt;=0.2 IU/mL and &gt;=0.5 IU/mL at Day 42</title>
        <description>RVNA titer against rabies virus was assessed using the RFFIT assay method. Participants with RVNA titer &gt;=0.2 IU/mL were considered as seropositive.</description>
        <time_frame>Day 42</time_frame>
        <population>Analysis was performed on PPAS. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: VRVg-2 Formulation 1</title>
            <description>VRVg-2 formulation 1 (Low), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Group 2:VRVg-2 Formulation 2</title>
            <description>VRVg-2 formulation 2 (Medium), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: VRVg-2 Formulation 3</title>
            <description>VRVg-2 formulation 3 (High), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: VRVg-1</title>
            <description>VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Imovax Rabies</title>
            <description>Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With RVNA Titers &gt;=0.2 IU/mL and &gt;=0.5 IU/mL at Day 42</title>
          <description>RVNA titer against rabies virus was assessed using the RFFIT assay method. Participants with RVNA titer &gt;=0.2 IU/mL were considered as seropositive.</description>
          <population>Analysis was performed on PPAS. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RVNA titers &gt;= 0.2 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="94.8" upper_limit="100"/>
                    <measurement group_id="O2" value="98.6" lower_limit="92.5" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="94.5" upper_limit="100"/>
                    <measurement group_id="O4" value="96.7" lower_limit="82.8" upper_limit="99.9"/>
                    <measurement group_id="O5" value="100" lower_limit="88.8" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RVNA titers &gt;= 0.5 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="94.8" upper_limit="100"/>
                    <measurement group_id="O2" value="98.6" lower_limit="92.5" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="94.5" upper_limit="100"/>
                    <measurement group_id="O4" value="96.7" lower_limit="82.8" upper_limit="99.9"/>
                    <measurement group_id="O5" value="100" lower_limit="88.8" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With RVNA Titers &gt;=0.2 IU/mL and &gt;=0.5 IU/mL at Month 7</title>
        <description>RVNA titer against rabies virus was assessed using the RFFIT assay method. Participants with RVNA titer &gt;= 0.2 IU/mL were considered as seropositive.</description>
        <time_frame>Month 7</time_frame>
        <population>Analysis was performed on PPAS. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: VRVg-2 Formulation 1</title>
            <description>VRVg-2 formulation 1 (Low), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Group 2:VRVg-2 Formulation 2</title>
            <description>VRVg-2 formulation 2 (Medium), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: VRVg-2 Formulation 3</title>
            <description>VRVg-2 formulation 3 (High), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: VRVg-1</title>
            <description>VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Imovax Rabies</title>
            <description>Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With RVNA Titers &gt;=0.2 IU/mL and &gt;=0.5 IU/mL at Month 7</title>
          <description>RVNA titer against rabies virus was assessed using the RFFIT assay method. Participants with RVNA titer &gt;= 0.2 IU/mL were considered as seropositive.</description>
          <population>Analysis was performed on PPAS. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RVNA titers &gt;= 0.2 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.4" lower_limit="84.1" upper_limit="98.2"/>
                    <measurement group_id="O2" value="93.0" lower_limit="84.3" upper_limit="97.7"/>
                    <measurement group_id="O3" value="100" lower_limit="94.4" upper_limit="100"/>
                    <measurement group_id="O4" value="92.6" lower_limit="75.7" upper_limit="99.1"/>
                    <measurement group_id="O5" value="87.1" lower_limit="70.2" upper_limit="96.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RVNA titers &gt;= 0.5 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5" lower_limit="57.4" upper_limit="81.5"/>
                    <measurement group_id="O2" value="77.5" lower_limit="66.0" upper_limit="86.5"/>
                    <measurement group_id="O3" value="92.2" lower_limit="82.7" upper_limit="97.4"/>
                    <measurement group_id="O4" value="74.1" lower_limit="53.7" upper_limit="88.9"/>
                    <measurement group_id="O5" value="74.2" lower_limit="55.4" upper_limit="88.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer Ratio (GMTR) of Rabies Virus Neutralizing Antibody 7 Days Following Vaccination 3 (Day 14/Day 0)</title>
        <description>RVNA titer against rabies virus was assessed using the RFFIT assay method. GMTRs were calculated as the ratio of GMTs 7 days post 3rd vaccination (i.e., on Day 14) and pre-vaccination on Day 0.</description>
        <time_frame>Day 0 (pre-dose) and Day 14 (7 days post-dose 3)</time_frame>
        <population>Analysis was performed on PPAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: VRVg-2 Formulation 1</title>
            <description>VRVg-2 formulation 1 (Low), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Group 2:VRVg-2 Formulation 2</title>
            <description>VRVg-2 formulation 2 (Medium), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: VRVg-2 Formulation 3</title>
            <description>VRVg-2 formulation 3 (High), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: VRVg-1</title>
            <description>VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Imovax Rabies</title>
            <description>Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer Ratio (GMTR) of Rabies Virus Neutralizing Antibody 7 Days Following Vaccination 3 (Day 14/Day 0)</title>
          <description>RVNA titer against rabies virus was assessed using the RFFIT assay method. GMTRs were calculated as the ratio of GMTs 7 days post 3rd vaccination (i.e., on Day 14) and pre-vaccination on Day 0.</description>
          <population>Analysis was performed on PPAS.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" lower_limit="9.37" upper_limit="17.1"/>
                    <measurement group_id="O2" value="17.9" lower_limit="13.3" upper_limit="24.1"/>
                    <measurement group_id="O3" value="24.8" lower_limit="19.0" upper_limit="32.3"/>
                    <measurement group_id="O4" value="13.7" lower_limit="9.27" upper_limit="20.3"/>
                    <measurement group_id="O5" value="15.6" lower_limit="10.6" upper_limit="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer Ratio of Rabies Virus Neutralizing Antibody 14 Days Following Vaccination 4 (Day 28/Day 0)</title>
        <description>RVNA titer against rabies virus was assessed using the RFFIT assay method. GMTRs were calculated as the ratio of GMTs 14 days post 4th vaccination (i.e., on Day 28) and pre-vaccination on Day 0.</description>
        <time_frame>Day 0 (pre-dose) and Day 28 (14 days post-dose 4)</time_frame>
        <population>Analysis was performed on PPAS. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: VRVg-2 Formulation 1</title>
            <description>VRVg-2 formulation 1 (Low), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Group 2:VRVg-2 Formulation 2</title>
            <description>VRVg-2 formulation 2 (Medium), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: VRVg-2 Formulation 3</title>
            <description>VRVg-2 formulation 3 (High), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0</description>
          </group>
          <group group_id="O4">
            <title>Group 4: VRVg-1</title>
            <description>VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Imovax Rabies</title>
            <description>Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer Ratio of Rabies Virus Neutralizing Antibody 14 Days Following Vaccination 4 (Day 28/Day 0)</title>
          <description>RVNA titer against rabies virus was assessed using the RFFIT assay method. GMTRs were calculated as the ratio of GMTs 14 days post 4th vaccination (i.e., on Day 28) and pre-vaccination on Day 0.</description>
          <population>Analysis was performed on PPAS. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9" lower_limit="24.6" upper_limit="41.3"/>
                    <measurement group_id="O2" value="46.4" lower_limit="35.3" upper_limit="61.0"/>
                    <measurement group_id="O3" value="67.0" lower_limit="54.4" upper_limit="82.6"/>
                    <measurement group_id="O4" value="30.0" lower_limit="18.5" upper_limit="48.7"/>
                    <measurement group_id="O5" value="48.6" lower_limit="35.6" upper_limit="66.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer Ratio of Rabies Virus Neutralizing Antibody 14 Days Following Vaccination 5 (Day 42/Day 0)</title>
        <description>RVNA titer against rabies virus was assessed using the RFFIT assay method. GMTRs were calculated as the ratio of GMTs 14 days post 5th vaccination (i.e., on Day 42) and pre-vaccination on Day 0.</description>
        <time_frame>Day 0 (Pre-dose) and Day 42 (14 days Post-dose 5)</time_frame>
        <population>Analysis was performed on PPAS. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: VRVg-2 Formulation 1</title>
            <description>VRVg-2 formulation 1 (Low), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Group 2:VRVg-2 Formulation 2</title>
            <description>VRVg-2 formulation 2 (Medium), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: VRVg-2 Formulation 3</title>
            <description>VRVg-2 formulation 3 (High), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: VRVg-1</title>
            <description>VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Imovax Rabies</title>
            <description>Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer Ratio of Rabies Virus Neutralizing Antibody 14 Days Following Vaccination 5 (Day 42/Day 0)</title>
          <description>RVNA titer against rabies virus was assessed using the RFFIT assay method. GMTRs were calculated as the ratio of GMTs 14 days post 5th vaccination (i.e., on Day 42) and pre-vaccination on Day 0.</description>
          <population>Analysis was performed on PPAS. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.7" lower_limit="65.6" upper_limit="99.3"/>
                    <measurement group_id="O2" value="96.8" lower_limit="75.0" upper_limit="125"/>
                    <measurement group_id="O3" value="153" lower_limit="125" upper_limit="188"/>
                    <measurement group_id="O4" value="69.0" lower_limit="46.4" upper_limit="103"/>
                    <measurement group_id="O5" value="89.9" lower_limit="64.8" upper_limit="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer Ratio of Rabies Virus Neutralizing Antibody 6 Months Following Last Vaccination (Month 7/Day 0)</title>
        <description>RVNA titer against rabies virus was assessed using the RFFIT assay method. GMTRs were calculated as the ratio of GMTs 6 month post last vaccination on Month 7 and pre-vaccination on Day 0.</description>
        <time_frame>Day 0 (Pre-dose) and Month 7 (6 Months Post Last Vaccination)</time_frame>
        <population>Analysis was performed on PPAS. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: VRVg-2 Formulation 1</title>
            <description>VRVg-2 formulation 1 (Low), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Group 2:VRVg-2 Formulation 2</title>
            <description>VRVg-2 formulation 2 (Medium), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: VRVg-2 Formulation 3</title>
            <description>VRVg-2 formulation 3 (High), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: VRVg-1</title>
            <description>VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Imovax Rabies</title>
            <description>Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer Ratio of Rabies Virus Neutralizing Antibody 6 Months Following Last Vaccination (Month 7/Day 0)</title>
          <description>RVNA titer against rabies virus was assessed using the RFFIT assay method. GMTRs were calculated as the ratio of GMTs 6 month post last vaccination on Month 7 and pre-vaccination on Day 0.</description>
          <population>Analysis was performed on PPAS. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.86" lower_limit="6.66" upper_limit="11.8"/>
                    <measurement group_id="O2" value="9.71" lower_limit="7.68" upper_limit="12.3"/>
                    <measurement group_id="O3" value="15.5" lower_limit="12.6" upper_limit="19.0"/>
                    <measurement group_id="O4" value="9.27" lower_limit="6.26" upper_limit="13.7"/>
                    <measurement group_id="O5" value="10.1" lower_limit="6.49" upper_limit="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Complete Virus Neutralization at Starting Dilution (1/5) of Rapid Fluorescent Focus Inhibition Test Assay at Day 0</title>
        <description>Complete virus neutralization was defined as absence of fluorescent cells at the participant/time point level at the starting dilution (1/5) of the RFFIT assay. Percentage of participants with complete virus neutralization were reported.</description>
        <time_frame>Day 0</time_frame>
        <population>Analysis was performed on PPAS. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: VRVg-2 Formulation 1</title>
            <description>VRVg-2 formulation 1 (Low), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Group 2:VRVg-2 Formulation 2</title>
            <description>VRVg-2 formulation 2 (Medium), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: VRVg-2 Formulation 3</title>
            <description>VRVg-2 formulation 3 (High), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: VRVg-1</title>
            <description>VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Imovax Rabies</title>
            <description>Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Complete Virus Neutralization at Starting Dilution (1/5) of Rapid Fluorescent Focus Inhibition Test Assay at Day 0</title>
          <description>Complete virus neutralization was defined as absence of fluorescent cells at the participant/time point level at the starting dilution (1/5) of the RFFIT assay. Percentage of participants with complete virus neutralization were reported.</description>
          <population>Analysis was performed on PPAS. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="4.8"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="5.1"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="10.3"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Complete Virus Neutralization at Starting Dilution (1/5) of Rapid Fluorescent Focus Inhibition Test Assay at Day 14</title>
        <description>Complete virus neutralization was defined as absence of fluorescent cells at the participant/time point level at the starting dilution (1/5) of the RFFIT assay. Percentage of participants with complete virus neutralization were reported.</description>
        <time_frame>Day 14</time_frame>
        <population>Analysis was performed on PPAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: VRVg-2 Formulation 1</title>
            <description>VRVg-2 formulation 1 (Low), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Group 2:VRVg-2 Formulation 2</title>
            <description>VRVg-2 formulation 2 (Medium), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: VRVg-2 Formulation 3</title>
            <description>VRVg-2 formulation 3 (High), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: VRVg-1</title>
            <description>VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Imovax Rabies</title>
            <description>Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Complete Virus Neutralization at Starting Dilution (1/5) of Rapid Fluorescent Focus Inhibition Test Assay at Day 14</title>
          <description>Complete virus neutralization was defined as absence of fluorescent cells at the participant/time point level at the starting dilution (1/5) of the RFFIT assay. Percentage of participants with complete virus neutralization were reported.</description>
          <population>Analysis was performed on PPAS.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.2" lower_limit="68.0" upper_limit="87.8"/>
                    <measurement group_id="O2" value="89.3" lower_limit="80.1" upper_limit="95.3"/>
                    <measurement group_id="O3" value="93.0" lower_limit="84.3" upper_limit="97.7"/>
                    <measurement group_id="O4" value="82.9" lower_limit="66.4" upper_limit="93.4"/>
                    <measurement group_id="O5" value="85.3" lower_limit="68.9" upper_limit="95.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Complete Virus Neutralization at Starting Dilution (1/5) of Rapid Fluorescent Focus Inhibition Test Assay at Day 28</title>
        <description>Complete virus neutralization was defined as absence of fluorescent cells at the participant/time point level at the starting dilution (1/5) of the RFFIT assay. Percentage of participants with complete virus neutralization were reported.</description>
        <time_frame>Day 28</time_frame>
        <population>Analysis was performed on PPAS. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: VRVg-2 Formulation 1</title>
            <description>VRVg-2 formulation 1 (Low), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Group 2:VRVg-2 Formulation 2</title>
            <description>VRVg-2 formulation 2 (Medium), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: VRVg-2 Formulation 3</title>
            <description>VRVg-2 formulation 3 (High), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: VRVg-1</title>
            <description>VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Imovax Rabies</title>
            <description>Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Complete Virus Neutralization at Starting Dilution (1/5) of Rapid Fluorescent Focus Inhibition Test Assay at Day 28</title>
          <description>Complete virus neutralization was defined as absence of fluorescent cells at the participant/time point level at the starting dilution (1/5) of the RFFIT assay. Percentage of participants with complete virus neutralization were reported.</description>
          <population>Analysis was performed on PPAS. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.8" lower_limit="83.9" upper_limit="97.6"/>
                    <measurement group_id="O2" value="94.6" lower_limit="86.7" upper_limit="98.5"/>
                    <measurement group_id="O3" value="98.6" lower_limit="92.3" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="89.1" upper_limit="100"/>
                    <measurement group_id="O5" value="93.9" lower_limit="79.8" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Complete Virus Neutralization at Starting Dilution (1/5) of Rapid Fluorescent Focus Inhibition Test Assay at Day 42</title>
        <description>Complete virus neutralization was defined as absence of fluorescent cells at the participant/time point level at the starting dilution (1/5) of the RFFIT assay. Percentage of participants with complete virus neutralization were reported.</description>
        <time_frame>Day 42</time_frame>
        <population>Analysis was performed on PPAS. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: VRVg-2 Formulation 1</title>
            <description>VRVg-2 formulation 1 (Low), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Group 2:VRVg-2 Formulation 2</title>
            <description>VRVg-2 formulation 2 (Medium), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: VRVg-2 Formulation 3</title>
            <description>VRVg-2 formulation 3 (High), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: VRVg-1</title>
            <description>VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Imovax Rabies</title>
            <description>Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Complete Virus Neutralization at Starting Dilution (1/5) of Rapid Fluorescent Focus Inhibition Test Assay at Day 42</title>
          <description>Complete virus neutralization was defined as absence of fluorescent cells at the participant/time point level at the starting dilution (1/5) of the RFFIT assay. Percentage of participants with complete virus neutralization were reported.</description>
          <population>Analysis was performed on PPAS. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1" lower_limit="89.9" upper_limit="99.6"/>
                    <measurement group_id="O2" value="93.2" lower_limit="84.9" upper_limit="97.8"/>
                    <measurement group_id="O3" value="94.1" lower_limit="85.6" upper_limit="98.4"/>
                    <measurement group_id="O4" value="100" lower_limit="88.8" upper_limit="100"/>
                    <measurement group_id="O5" value="93.9" lower_limit="79.8" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Complete Virus Neutralization at Starting Dilution (1/5) of Rapid Fluorescent Focus Inhibition Test Assay at Month 7</title>
        <description>Complete virus neutralization was defined as absence of fluorescent cells at the participant/time point level at the starting dilution (1/5) of the RFFIT assay. Percentage of participants with complete virus neutralization were reported.</description>
        <time_frame>Month 7</time_frame>
        <population>Analysis was performed on PPAS. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: VRVg-2 Formulation 1</title>
            <description>VRVg-2 formulation 1 (Low), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Group 2:VRVg-2 Formulation 2</title>
            <description>VRVg-2 formulation 2 (Medium), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: VRVg-2 Formulation 3</title>
            <description>VRVg-2 formulation 3 (High), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: VRVg-1</title>
            <description>VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Imovax Rabies</title>
            <description>Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Complete Virus Neutralization at Starting Dilution (1/5) of Rapid Fluorescent Focus Inhibition Test Assay at Month 7</title>
          <description>Complete virus neutralization was defined as absence of fluorescent cells at the participant/time point level at the starting dilution (1/5) of the RFFIT assay. Percentage of participants with complete virus neutralization were reported.</description>
          <population>Analysis was performed on PPAS. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.1" lower_limit="86.3" upper_limit="99.0"/>
                    <measurement group_id="O2" value="88.7" lower_limit="79.0" upper_limit="95.0"/>
                    <measurement group_id="O3" value="100" lower_limit="94.5" upper_limit="100"/>
                    <measurement group_id="O4" value="85.2" lower_limit="66.3" upper_limit="95.8"/>
                    <measurement group_id="O5" value="93.5" lower_limit="78.6" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Immediate Unsolicited Adverse Events</title>
        <description>An adverse event was defined as any untoward medical occurrence in a participant who received study drug and does not necessary have to have a causal relationship with treatment. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report form (CRF) in terms of diagnosis and/or onset post-vaccination. All participants were observed for 30 minutes after any vaccination, and any unsolicited AEs occurred during that time were recorded as immediate unsolicited AEs in the CRF. Immediate AEs considered as related to vaccination were recorded as immediate unsolicited adverse reactions (ARs).</description>
        <time_frame>Within 30 Minutes After any Vaccination</time_frame>
        <population>Analysis was performed on safety analysis set (SafAS) that included participant who had received at least one least one dose of the study vaccine and were analyzed according to the actual treatment received. 1 participant of Group 4 received Imovax Rabies, and thus counted in Group 5 for safety analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: VRVg-2 Formulation 1</title>
            <description>VRVg-2 formulation 1 (Low), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Group 2:VRVg-2 Formulation 2</title>
            <description>VRVg-2 formulation 2 (Medium), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: VRVg-2 Formulation 3</title>
            <description>VRVg-2 formulation 3 (High), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: VRVg-1</title>
            <description>VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Imovax Rabies</title>
            <description>Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Immediate Unsolicited Adverse Events</title>
          <description>An adverse event was defined as any untoward medical occurrence in a participant who received study drug and does not necessary have to have a causal relationship with treatment. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report form (CRF) in terms of diagnosis and/or onset post-vaccination. All participants were observed for 30 minutes after any vaccination, and any unsolicited AEs occurred during that time were recorded as immediate unsolicited AEs in the CRF. Immediate AEs considered as related to vaccination were recorded as immediate unsolicited adverse reactions (ARs).</description>
          <population>Analysis was performed on safety analysis set (SafAS) that included participant who had received at least one least one dose of the study vaccine and were analyzed according to the actual treatment received. 1 participant of Group 4 received Imovax Rabies, and thus counted in Group 5 for safety analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Immediate Unsolicited AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immediate Unsolicited AR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With at Least One Solicited Injection Site Reactions</title>
        <description>A solicited reaction (SR) was an AR observed and reported under conditions (symptoms and onset) prelisted (i.e., solicited) in the CRF and considered as related to vaccination. An AR was all noxious and unintended responses to a medicinal product related to any dose. Solicited injection site reactions included pain, erythema and swelling at and around the injection site.</description>
        <time_frame>Within 7 Days After any and each vaccination (Vaccination 1, 2, 3, 4 and 5)</time_frame>
        <population>Analysis performed on SafAS. Here, 'number analyzed' = participants with available data for each specified category.1 participant of Group 4 received Imovax Rabies, and thus counted in Group 5 for safety analysis. At Vaccination 2, 1 participant of Group 1 received Group 2 vaccine and thus counted in Group 2 for post-vaccination 2 safety analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: VRVg-2 Formulation 1</title>
            <description>VRVg-2 formulation 1 (Low), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Group 2:VRVg-2 Formulation 2</title>
            <description>VRVg-2 formulation 2 (Medium), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: VRVg-2 Formulation 3</title>
            <description>VRVg-2 formulation 3 (High), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: VRVg-1</title>
            <description>VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Imovax Rabies</title>
            <description>Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least One Solicited Injection Site Reactions</title>
          <description>A solicited reaction (SR) was an AR observed and reported under conditions (symptoms and onset) prelisted (i.e., solicited) in the CRF and considered as related to vaccination. An AR was all noxious and unintended responses to a medicinal product related to any dose. Solicited injection site reactions included pain, erythema and swelling at and around the injection site.</description>
          <population>Analysis performed on SafAS. Here, 'number analyzed' = participants with available data for each specified category.1 participant of Group 4 received Imovax Rabies, and thus counted in Group 5 for safety analysis. At Vaccination 2, 1 participant of Group 1 received Group 2 vaccine and thus counted in Group 2 for post-vaccination 2 safety analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain post-any vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Post-vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Post-vaccination 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Post-vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Post-vaccination 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Post-vaccination 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema post-any vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema Post-vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema Post-vaccination 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema Post-vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema Post-vaccination 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema Post-vaccination 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling post-any vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling Post-vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling Post-vaccination 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling Post-vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling Post-vaccination 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling Post-vaccination 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With at Least One Solicited Systemic Reactions</title>
        <description>A solicited reaction was an AR observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the CRF and considered as related to vaccination. An AR was all noxious and unintended responses to a medicinal product related to any dose. Solicited systemic reactions included fever, headache, malaise and myalgia.</description>
        <time_frame>Within 7 Days After any and each vaccination (Vaccination 1, 2, 3, 4 and 5)</time_frame>
        <population>Analysis performed on SafAS. Here, 'number analyzed' = participants with available data for each specified category.1 participant of Group 4 received Imovax Rabies, and thus counted in Group 5 for safety analysis. At Vaccination 2, 1 participant of Group 1 received Group 2 vaccine and thus counted in Group 2 for post-vaccination 2 safety analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: VRVg-2 Formulation 1</title>
            <description>VRVg-2 formulation 1 (Low), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Group 2:VRVg-2 Formulation 2</title>
            <description>VRVg-2 formulation 2 (Medium), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: VRVg-2 Formulation 3</title>
            <description>VRVg-2 formulation 3 (High), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: VRVg-1</title>
            <description>VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Imovax Rabies</title>
            <description>Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least One Solicited Systemic Reactions</title>
          <description>A solicited reaction was an AR observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the CRF and considered as related to vaccination. An AR was all noxious and unintended responses to a medicinal product related to any dose. Solicited systemic reactions included fever, headache, malaise and myalgia.</description>
          <population>Analysis performed on SafAS. Here, 'number analyzed' = participants with available data for each specified category.1 participant of Group 4 received Imovax Rabies, and thus counted in Group 5 for safety analysis. At Vaccination 2, 1 participant of Group 1 received Group 2 vaccine and thus counted in Group 2 for post-vaccination 2 safety analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever Post-any Vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever Post-vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever Post-vaccination 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever Post-vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever Post-vaccination 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="79"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever Post-vaccination 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache Post-any Vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache Post-vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache Post-vaccination 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache Post-vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache Post-vaccination 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache Post-vaccination 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise Post-any Vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise Post-vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise Post-vaccination 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise Post-vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise Post-vaccination 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise Post-vaccination 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia Post-any Vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia Post-vaccination 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia Post-vaccination 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia Post-vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia Post-vaccination 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="36"/>
                    <count group_id="O5" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia Post-vaccination 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With at Least One Unsolicited Adverse Events</title>
        <description>An AE was defined as any untoward medical occurrence in a participant who received study drug and does not necessary have to have a causal relationship with treatment. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the CRF in terms of diagnosis and/or onset post-vaccination.</description>
        <time_frame>Within 28 Days After any vaccination</time_frame>
        <population>Analysis was performed on SafAS. 1 participant of Group 4 received Imovax Rabies vaccine, and thus counted in Group 5 for safety analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: VRVg-2 Formulation 1</title>
            <description>VRVg-2 formulation 1 (Low), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Group 2:VRVg-2 Formulation 2</title>
            <description>VRVg-2 formulation 2 (Medium), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: VRVg-2 Formulation 3</title>
            <description>VRVg-2 formulation 3 (High), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: VRVg-1</title>
            <description>VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Imovax Rabies</title>
            <description>Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least One Unsolicited Adverse Events</title>
          <description>An AE was defined as any untoward medical occurrence in a participant who received study drug and does not necessary have to have a causal relationship with treatment. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the CRF in terms of diagnosis and/or onset post-vaccination.</description>
          <population>Analysis was performed on SafAS. 1 participant of Group 4 received Imovax Rabies vaccine, and thus counted in Group 5 for safety analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Serious Adverse Events (SAEs)</title>
        <description>An AE was defined as any untoward medical occurrence in a participant who received study drug and does not necessary have to have a causal relationship with treatment. An SAE was any untoward medical occurrence that at any dose resulted in death; life-threatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect or a medically important event.</description>
        <time_frame>From Day 0 up to Month 7</time_frame>
        <population>Analysis was performed on SafAS. 1 participant of Group 4 received Imovax Rabies vaccine, and thus counted in Group 5 for safety analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: VRVg-2 Formulation 1</title>
            <description>VRVg-2 formulation 1 (Low), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Group 2:VRVg-2 Formulation 2</title>
            <description>VRVg-2 formulation 2 (Medium), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: VRVg-2 Formulation 3</title>
            <description>VRVg-2 formulation 3 (High), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: VRVg-1</title>
            <description>VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: Imovax Rabies</title>
            <description>Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events (SAEs)</title>
          <description>An AE was defined as any untoward medical occurrence in a participant who received study drug and does not necessary have to have a causal relationship with treatment. An SAE was any untoward medical occurrence that at any dose resulted in death; life-threatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect or a medically important event.</description>
          <population>Analysis was performed on SafAS. 1 participant of Group 4 received Imovax Rabies vaccine, and thus counted in Group 5 for safety analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AE data were collected from Day 0 (post-vaccination 1) up to 28 days post any vaccination. SR data were collected within 7 days post any vaccination. SAE data were collected throughout the study (up to 6 months after last vaccination, i.e., up to Month 7).</time_frame>
      <desc>Analysis was performed on SafAS. A SR was an AE that was prelisted (i.e., solicited) in the CRF and considered to be related to vaccination (adverse drug reaction). An unsolicited AE was an observed AE that did not fulfill the conditions prelisted (i.e., solicited) in the CRF in terms of diagnosis and/or onset post-vaccination.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1: VRVg-2 Formulation 1</title>
          <description>VRVg-2 formulation 1 (Low), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
        </group>
        <group group_id="E2">
          <title>Group 2: VRVg-2 Formulation 2</title>
          <description>VRVg-2 formulation 2 (Medium), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
        </group>
        <group group_id="E3">
          <title>Group 3: VRVg-2 Formulation 3</title>
          <description>VRVg-2 formulation 3 (High), IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
        </group>
        <group group_id="E4">
          <title>Group 4: VRVg-1</title>
          <description>VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
        </group>
        <group group_id="E5">
          <title>Group 5: Imovax Rabies</title>
          <description>Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Facial Paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application Site Bruise</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" events="69" subjects_affected="29" subjects_at_risk="80"/>
                <counts group_id="E2" events="60" subjects_affected="32" subjects_at_risk="80"/>
                <counts group_id="E3" events="95" subjects_affected="38" subjects_at_risk="80"/>
                <counts group_id="E4" events="30" subjects_affected="14" subjects_at_risk="39"/>
                <counts group_id="E5" events="56" subjects_affected="24" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="41" subjects_affected="26" subjects_at_risk="80"/>
                <counts group_id="E2" events="20" subjects_affected="13" subjects_at_risk="80"/>
                <counts group_id="E3" events="35" subjects_affected="17" subjects_at_risk="80"/>
                <counts group_id="E4" events="21" subjects_affected="11" subjects_at_risk="39"/>
                <counts group_id="E5" events="35" subjects_affected="16" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="49" subjects_affected="25" subjects_at_risk="80"/>
                <counts group_id="E2" events="36" subjects_affected="22" subjects_at_risk="80"/>
                <counts group_id="E3" events="41" subjects_affected="20" subjects_at_risk="80"/>
                <counts group_id="E4" events="21" subjects_affected="11" subjects_at_risk="39"/>
                <counts group_id="E5" events="44" subjects_affected="19" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Headache events that occurred after 7 days post-vaccination were considered as unsolicited AE.</description>
                <counts group_id="E1" events="49" subjects_affected="26" subjects_at_risk="80"/>
                <counts group_id="E2" events="20" subjects_affected="12" subjects_at_risk="80"/>
                <counts group_id="E3" events="42" subjects_affected="21" subjects_at_risk="80"/>
                <counts group_id="E4" events="13" subjects_affected="10" subjects_at_risk="39"/>
                <counts group_id="E5" events="41" subjects_affected="15" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>Sanofi Pasteur</organization>
      <phone>800-633-1610 ext 1#</phone>
      <email>Contact-US@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

